If you have been reading about tirzepatide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
If recovery of usable ruthenium is a goal, an extremely pure technetium target is needed; if small traces of the minor actinides such as americium and curium are present in the target, they are likely to undergo fission and form more fission products which increase the radioactivity of the irradiated target. The formation of ruthenium-106 (half-life 374 days) from the 'fresh fission' is likely to increase the activity of the final ruthenium metal, which will then require a longer cooling time after irradiation before the ruthenium can be used. The actual separation of technetium-99 from spent nuclear fuel is a long process. During fuel reprocessing, it comes out as a component of the highly radioactive waste liquid. After sitting for several years, the radioactivity reduces to a level where extraction of the long-lived isotopes, including technetium-99, becomes feasible. A series of chemical processes yields technetium-99 metal of high purity.
=== Labeling and advertising === Studies conducted by the US Food and Drug Administration (FDA) from 2014 through 2019, determined that a majority of CBD products are not accurately labeled with the amount of CBD they contain. For example, a 2017 analysis of cannabidiol content in oil, tincture, or liquid vape products purchased online in the United States showed that 69% were mislabeled, with 43% having higher and 26% having lower content than stated on product labels. In 2020, the FDA conducted a study of 147 CBD products and found that half contained THC. From 2015 through 2022, the FDA issued dozens of warning letters to American manufacturers of CBD products for false advertising and illegal interstate marketing of CBD as an unapproved drug to treat diseases, such as cancer, osteoarthritis, symptoms of opioid withdrawal, Alzheimer's disease, and pet disorders. Chemical analysis of CBD products found that many did not contain the levels of CBD claimed in advertising. In December 2020, the US Federal Trade Commission initiated a law enforcement crackdown on American companies marketing CBD products as unapproved drugs. The warning also applied to hemp CBD capsules and oil that were being marketed illegally while not adhering to the federal definition of a dietary supplement.
Evidence from the study of bone microanatomy of Neanderthal remains from Sesselfelsgrotte (Germany), indicative of an overall similar growth trajectory of Neanderthals and modern humans during their early life, is presented by Miszkiewicz et al. (2026), who also report the presence of probably pathological interglobular dentin in the studied fossil material that might be evidence of a metabolic bone disease. Zollikofer et al. (2026) compare the morphology of Neanderthal pelves from Sima de las Palomas (Spain) and Dederiyeh Cave (Syria) with those of modern humans, reporting evidence of morphological similarities of pelvic regions associated with childbirth, as well as evidence of differences in pelvic regions associated with locomotion. Sorrentino et al. (2026) report evidence of presence of overall more robust calcaneus in Neanderthals compared to modern humans, with the closest similarity to calcanei of highly mobile, unshod modern human groups. Verheijen et al. (2026) study evidence of Neanderthal activity in faunal remains from the Lehringen site (Germany), reporting evidence of defleshing of a straight-tusked elephant when its carcass was in fresh state and evidence of butchery of a beaver, bear and aurochs. Evidence indicating that exploitation of shellfish by Neanderthals occupying the Cave of Los Aviones (Spain) happened primarily during the colder months of the year is presented by García-Escárzaga et al. (2026).
This same proposal was proposed again in 1976, but further studies indicated that the recurrence rate was not better. In 1888, treatments were tried that entered the abdomen to make reattachments. Some did not agree with this and suggested an approach through the inguinal canal. In 1898, further abdominal approaches were proposed. No further advances have been noted until 1961 when reattachment of the anterior vaginal wall to Cooper's ligament began to be used. Unfortunately, posterior vaginal wall prolapse occurred in some patients even though the anterior repair was successful. In 1955, using mesh to support pelvic structures became common. In 1970, tissue from pigs began to be used to strengthen the anterior vaginal wall in surgery. Beginning in 1976, improvement in suturing began along with the surgical removal of the vagina being used to treat prolapse of the bladder. In 1991, assumptions about the detailed anatomy of the pelvic support structures began to be questioned regarding the existence of some pelvic structures and the non-existence of others. More recently, stem cells and robot-assisted laparoscopic surgery have been used to treat cystoceles.
Sources: en.wikipedia.org
Duffy announced later that year that work would begin in 2027 and would cost $7 billion, and in May 2026 Amtrak selected out of three finalists a joint venture of Skanska and Halmar International as developer and Vishaan Chakrabarti's Practice for Architecture and Urbanism (PAU) as lead design architect. The approved plan would keep Madison Square Garden in place and rebuild the passenger facilities beneath it. In June 2026, Amtrak and Penn Transformation Partners released renderings for an approximately $8 billion redesign of Penn Station that would retain Madison Square Garden while creating a larger, light-filled station inspired by the original Pennsylvania Station. Later that month, a pre-development agreement (PDA) was finalized, with the project estimated to break ground by the end of 2027. Amtrak also offered to re-add the MTA as a partner in the station's reconstruction, but the MTA declined.
== Applications == HBsAg made through recombinant DNA is used to make the hepatitis B vaccine. It has a very good efficacy of about 95%, with protection lasting for more than 30 years, even after the anti-HbsAg antigen titers have fallen. The RTS,S also makes use of HBsAg. It is a mixture of a version of malaria surface antigen grafted to HBsAg (RTS) and ordinary HBsAg (S), both made through recombinant DNA. Much like ordinary HBsAg, these two are able to assemble into virus-like particles that are soluble in water.
=== Exogenous antigens === Exogenous antigens are antigens that have entered the body from the outside, for example, by inhalation, ingestion or injection. The immune system's response to exogenous antigens is often subclinical. By endocytosis or phagocytosis, exogenous antigens are taken into the antigen-presenting cells (APCs) and processed into fragments. APCs then present the fragments to T helper cells (CD4+) by the use of class II histocompatibility molecules on their surface. Some T cells are specific for the peptide:MHC complex. They become activated and start to secrete cytokines, substances that activate cytotoxic T lymphocytes (CTL), antibody-secreting B cells, macrophages and other particles. Some antigens start out as exogenous and later become endogenous (for example, intracellular viruses). Intracellular antigens can be returned to circulation upon the destruction of the infected cell.
== Transport mechanisms == The transport of norepinephrine back into presynaptic cell is made possible by the cotransport with Na+ and Cl−. The sequential binding of the ions results in the eventual reuptake of norepinephrine. The ion gradients of Na+ and Cl− make this reuptake energetically favorable. The gradient is generated by the Na+/K+-ATPase which transports three sodium ions out and two potassium ions into the cell. NETs have conductances similar to those of ligand-gated ion channels. The expression of NET results in a leak-channel activity.
Small-flowered Division: Flowers (1.5–)2–12(–18) cm across Armandii Group: Cultivars belonging to, or derived from, species classified in subsection Meyenianae (Tamura) M. Johnson, mainly C. armandii. Atragene Group: Cultivars belonging to, or derived from, species classified in subgenus Atragene (L.) Torrey & A. Gray, such as C. alpina, C. chiisanensis, C. fauriei, C. koreana, C. macropetala, C. ochotensis, C. sibirica, C. turkestanica. The former Alpina Group and Macropetala Group are included here. Historically, the Alpina Group was used for single-flowered cultivars, and double-flowered cultivars were assigned to the Macropetala Group. Cirrhosa Group: Cultivars belonging to, or derived mainly from, C. cirrhosa. Flammula Group: Cultivars with at least one parent belonging to, or derived from, species classified in section Flammula DC. (excluding subsection Meyenianae (Tamura)M. Johnson), such as C. angustifolia, C. flammula, C. recta, C. terniflora. Forsteri Group: Cultivars belonging to, or derived from, species classified in section Novae-zeelandiae M. Johnson (native to Australia and New Zealand) such as C. australis, C. foetida, C. forsteri, C. marata, C. marmoraria, C. paniculata, C. petriei. Heracleifolia Group: Cultivars with at least one parent belonging to, or derived from, species classified in subgenus Tubulosa (Decne.) Grey-Wilson, such as C. heracleifolia, C. stans, C. tubulosa. Integrifolia Group: Cultivars belonging to, or derived mainly from, C. integrifolia. Includes the Diversifolia Group (which covered C. × diversifolia (C. integrifolia × C.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。